An estimated 4000 deaths occur in the United States each year due to pneumococcus,withthe vast majority occurring in adults.Pneumococcal polysaccharide vaccine, PPSV23 (PNEUMOVAX®), has been recommended for the prevention of invasive pneumococcal disease (IPD) in adults since 1997. A single dose...
Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23,...
the multiplicity of different strains of the pathogen, with over ninety serotypes ofS. pneumoniaeidentified to date [5]. Currently, 13-valent (PCV13; Prevenar 13®) and 23-valent (PPSV23; Pneumovax®) are the only vaccines currently approved in France for the prevention of PD in adults...
Two pneumococcal vaccines[18,19]are currently FDA-approved for adults: Pneumococcal polysaccharide vaccine (PPSV23; Pneumovax®23); and Pneumococcal conjugate vaccine (PCV13; Prevnar 13®). ACIP recommendsbothvaccines for those aged 65 or older.[18]ACIP recommends PPSV23onlyfor adults aged 19...
alone or a 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme, LLC) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme, LLC). Additional recommendations for use of PCV20 exist for adults who started their pneumococ...